Related Experiment Video
Updated: Jul 20, 2026
12:35
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
Published on: March 17, 2012
Establishing a standardized therapeutic testing protocol for spinal muscular atrophy
Li-Kai Tsai1, Ming-Shung Tsai, Tzer-Bin Lin
1Department of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan.
Neurobiology of Disease
|September 6, 2006
Summary
A new testing protocol for spinal muscular atrophy (SMA) using type III-specific mouse models demonstrates efficacy. This system successfully evaluated valproic acid (VPA) as a potential therapeutic intervention for SMA.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Spinal muscular atrophy (SMA) lacks a standardized preclinical testing system.
- Previous development of type III-specific SMA mouse models offers potential for therapeutic evaluation.
Purpose of the Study:
- To establish and validate a preclinical testing protocol for SMA.
- To investigate the therapeutic potential of valproic acid (VPA) in SMA mouse models.
Main Methods:
- Generation of type III-specific SMA mouse models.
- Development and application of a standardized testing protocol.
- Assessment of valproic acid (VPA) treatment effects on SMA mice.
Main Results:
- SMA mice exhibited characteristic deformities, muscle atrophy, impaired motor function, reduced compound muscle action potential, and lower motoneuron density.
- Valproic acid (VPA) treatment attenuated motoneuron death and increased spinal SMN protein levels.
- Partial normalization of motor function was observed in VPA-treated SMA mice.
Conclusions:
- The developed testing protocol is suitable for a standardized preclinical therapeutic testing system for SMA.
- Valproic acid (VPA) shows promise as a potential therapeutic agent for SMA, warranting further investigation.
